Amedisys Reports Fourth Quarter and Year-End 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Amedisys (AMED) Misses Q4 EPS by 9c
February 21, 2024 4:34 PM ESTAmedisys (NASDAQ: AMED) reported Q4 EPS of $0.94, $0.09 worse than the analyst estimate of $1.03. Revenue for the quarter came in at $570.8 million versus the consensus estimate of $567.4 million.
For earnings history and earnings-related data on Amedisys (AMED) click here.
... More